SNC
ONCT

Stifel Nicolaus & Co’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Stifel Nicolaus & Co’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$54.7K Buy
19
+4
+27% +$19.9K ﹤0.01% 1460
2013
Q2 		$141K Buy
+15
New +$116K ﹤0.01% 1316

Other funds holding ONCT

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Stifel Nicolaus & Co's ONCT Position: Q3 2013 in Review

Stifel Nicolaus & Co increased its Oncternal Therapeutics, Inc. Common Stock (ONCT) stake by 27% in Q3 2013, buying an estimated $19.9K and bringing the position to 19 shares worth $54.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1460.

Stifel Nicolaus & Co first reported a position in ONCT in Q2 2013 and has held it in 2 quarters since. The position peaked at $141K in Q2 2013. 58 funds tracked by Wall St. Rank hold ONCT as of Q3 2013.

  • Stifel Nicolaus & Co held 19 shares of Oncternal Therapeutics, Inc. Common Stock worth $54.7K as of Q3 2013.
  • Stifel Nicolaus & Co bought 4 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2013, an estimated $19.9K.
  • Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of Stifel Nicolaus & Co's portfolio in Q3 2013, its #1460 holding.
  • Stifel Nicolaus & Co first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 2 quarters since.
  • Stifel Nicolaus & Co's Oncternal Therapeutics, Inc. Common Stock position peaked at $141K in Q2 2013.
  • 58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.